o签署的客户订单的合同价值增加了​​54％；从2022年的8500万英镑（不包括Covid-19疫苗制造）增长到2023年的1.31亿英镑，o在业务发展渠道中增加了51％； from $291 million to $438 million from January to December 2023 • Significant commercial momentum with strong demand for OXB's CDMO services across all key viral vector types, with an expanded client portfolio including 35 clients and 51 programmes as of April 2024 (April 2023: 18 clients and 34 programmes), now includes new clients gained through Oxford Biomedica (France) • Acquisition of ABL Europe (recently renamed Oxford Biomedica (France)) from Institut Mérieux, completed post-period end, enhances OXB's bioprocessing and manufacturing footprint in the EU, strengthening the Group's multi-vector, multi-site model spanning the UK, US and the EU • Reiterates its existing financial guidance communicated to the market • Briefing and webcast for analysts to be held today at 13:00 BST / 08:00 ET – see details below Oxford, UK - 2024年4月29日：牛津BioMedica PLC（“牛津生物群”或“ oft the Group”）（LSE：Oxb），一种质量和创新为主导的细胞和基因治疗CDMO，今天宣布了其截至2023年12月31日的年度结果。牛津生物组织首席执行官弗兰克·马蒂亚斯（Frank Mathias）博士说：“ 2023年是牛津生物群的转型一年。我们正在建立自己的地位，作为全球纯戏细胞和基因疗法CDMO，通过我们的“ One Oxb”策略，正在统一我们在英国，美国和欧盟的运营，包括我们在法国新获得的地点。